Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.

Ingelheim, Germany, 20 May 2015 Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.

Until recently, treatment options for patients with IPF were limited. Nintedanib* is the first targeted treatment for IPF to consistently demonstrate its efficacy in three trials. Nintedanib* slows disease progression by reducing the decline in lung function by 50% in a broad range of IPF patient types**.1Nintedanib* significantly reduced the risk of adjudicated acute exacerbations‡ by 68%.1

Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim
Professor Klaus
Dugi, Chief Medical
Officer, Boehringer
Ingelheim

Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim commented: “We are pleased to see that nintedanib* is being suggested as an option for treating patients with IPF in the update of the 2011 evidence based treatment guidelines. This is a very important step in improving care for IPF patients”.

Boehringer Ingelheim strongly believes that there is a substantial unmet need for patients living with IPF. Patients suffering from this chronic, debilitating disease could benefit from a treatment like nintedanib* which significantly slows the decline in lung function and has a manageable side effect profile.1

IPF is a fatal lung disease, with a median survival of 2 – 3 years after diagnosis.2 It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and difficulty breathing. Worldwide, IPF affects as many as 14 – 43 people per 100,000,3,4 most commonly over the age of 50.5

Notes to Editor

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Footnotes

*Nintedanib is approved under the brand name OFEV® in the US and EU for use in patients with IPF. Nintedanib is under regulatory review by health authorities in other countries
‡Adjudicated exacerbations was a pre-specified sensitivity analysis in the pooled data set. Time to first investigator-reported exacerbation was a secondary endpoint which was met in TOMORROW and INPULSIS®-2 but not in INPULSIS®-1
**INPULSIS® recruited a broad range of patient types – similar to those seen in clinical practice including patients with early disease (FVC > 90% pred), no honeycombing on HRCT and/or concomitant emphysema

Referências

  1. Richeldi L, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014; 370:2071-82.
  2. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
  3. Raghu G, et al. Incidence and prevalence of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2006;174:810-816.
  4. Fernández Pérez E, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129-37.
  5. American Thoracic Society. Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. Am J Respir Crit Care Med. 2000;161:646–664.